Sector
PharmaceuticalsOpen
₹197.67Prev. Close
₹197.67Turnover(Lac.)
₹7,456.82Day's High
₹206.09Day's Low
₹195.552 Week's High
₹307.952 Week's Low
₹181.73Book Value
₹56.95Face Value
₹10Mkt Cap (₹ Cr.)
27,260.22P/E
36.53EPS
5.41Divi. Yield
0.0718 Jul 2025
12:00 AM
Board Meeting
Agenda : Audited Result
13 Jun 2025
12:00 AM
AGM
Announcement Date: 13 Jun, 2025
14 May 2025
12:00 AM
Dividend
Dividend Amount: 0.14
Record Date: 16 Jul, 2025
The company stated in its filing with the bourses that its remains committed to maintain highest compliance standards.
Piramal Critical Care has reserved commercialisation rights for the EU, UK, and Norway and will look after Neoatricon in these regions.
This month, the US FDA inspected the facility and after inspection issued a Form 483 of six observations as the company has to improve compliance in this regard.
In response to growing demand of IA, capacity expansions are under way at both Dahej and Digwal facilities, with month-on-month production growth.
As part of long-term strategy PCC has seen a number of product launches during recent times which are building block towards market presence in generic injectables.
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 1,324.35 | 1,322.95 | 1,193.32 | 1,185.91 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 6,128.19 | 5,389.12 | 4,068.47 | 3,937.21 |
Net Worth | 7,452.54 | 6,712.07 | 5,261.79 | 5,123.12 |
Minority Interest |
No Record Found
No Record Found
No Record Found
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Gross Sales | 9,151.18 | 8,171.16 | 7,081.55 | 6,559.1 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 9,151.18 | 8,171.16 | 7,081.55 | 6,559.1 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 207.74 | 234.88 | 279.44 | 334.83 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,631.2 | 78.71 | 3,92,063.33 | 753.53 | 0.98 | 5,566.68 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 5,866 | 66.67 | 1,55,749.09 | 557 | 0.51 | 2,357 | 561.08 |
Cipla Ltd CIPLA | 1,517.7 | 23.7 | 1,22,429.01 | 1,303.13 | 1.06 | 4,501.66 | 397.38 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,514.7 | 59.82 | 1,18,922.69 | 551 | 0.17 | 2,567 | 224.34 |
Dr Reddys Laboratories Ltd DRREDDY | 1,248.1 | 15.11 | 1,04,168.14 | 2,961.2 | 0.64 | 7,788.7 | 345.74 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairperson
Nandini Piramal
Executive Director & CEO
PETER D DEYOUNG
Executive Director & CFO
Vivek Valsaraj
Non-Exec & Non-Independent Dir
Amit Jain
Independent Non Exe. Director
S Rama Dorai
Independent Non Exe. Director
Jairaj Manohar Purandare
Independent Non Exe. Director
Sridhar Gorthi
Independent Non Exe. Director
Peter Stevenson
Non-Exec & Non-Independent Dir
Nathalie Leitch
Independent Non Exe. Director
Vibha Paul Rishi
Company Sec. & Compli. Officer
Tanya Sanish
Ground Floor Piramal Ananta,
Agastya Corp.Park LBS MargKurl,
Maharashtra - 400070
Tel: 91-22-3802-3000/4000
Website: http://www.piramalpharma.com
Email: corporate.secretarial@piramal.com
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-...
Read More
Reports by Piramal Pharma Ltd
What is the Piramal Pharma Ltd share price today?
What is the Market Cap of Piramal Pharma Ltd?
What is the PE and PB ratio of Piramal Pharma Ltd?
What is the 52 Week High and Low of Piramal Pharma Ltd?
What is the CAGR of Piramal Pharma Ltd?
What is the shareholding pattern of Piramal Pharma Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
